Rentschler names Benedikt von Braun­muehl as CEO; Catal­ent grabs David McEr­lane from Lon­za as bi­o­log­ics lead

Benedikt von Braun­muehl has been re­vealed as Rentschler Bio­phar­ma’s new CEO. Mean­while, Catal­ent al­so an­nounced that David McEr­lane is the CD­MO’s new group pres­i­dent of its bi­o­log­ic seg­ment.

Von Braun­muehl, the for­mer CEO of HM­NC Brain Health, re­placed Frank Math­ias, who shift­ed to Ox­ford Bio­med­ica in Feb­ru­ary af­ter sev­en years at Rentschler. Tues­day marks von Braun­muehl’s first day on the job.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER